Alzheimer's disease, the commonest cause of senile and presenile dementia, is characterised pathologically by the presence of large numbers of argyrophilic plaques and neurofibrillary tangles in the hippocampus and neocortex of the brain. 1 The stimulus to the development of these abnormal structures is unknown. One view proposes that argyrophilic plaque development may be attributable to disordered immune function.2 While evidence put forward so far in support of this view is inconclusive, the possibility that changes in the expression of cellular antigens with advancing age may have a role in the development of age related diseases such as Alzheimer's disease, is a reasonable one. An attempt was therefore made to raise monoclonal antibodies that react specifically with cellular components from aged humans, and we report here one result of such an attempt; the generation of a monoclonal antibody that reacts intensely with the congophilic elements in human Alzheimer brain, identified as SMP.
Methods

GENERATION OF MONOCLONAL ANTIBODY SMP
The antibody was produced by cells formed by fusion of mouse myeloma cells with spleen lymphocytes taken from a mouse that had been immunised with pooled peripheral blood mononuclear cells from several aged human donors (aged 71-82 years). One mouse (BALB/C) was first hyperimmunised with (8 mg/ml, Sigma) for a further 30 minutes. Sections were washed again and substrate added (2 mg naphthol As-Mx phosphate (Sigma) dissolved in 0-2 ml of dimethyl formamide and made up to 10 ml with 0-1 M Tris buffer, pH 8-2, to which was added I mg of 1200 levamisole (to block endogenous enzyme activity) and I mg of fast red TR salt). The substrate was filtered before use and applied directly to the slide. Positive reaction gave a red precipitate.
In some experiments application of neat SMP monoclonal antibody for 30 minutes was followed by peroxidase conjugated antiserum to mouse immunoglobulin and the diaminobenzidine reaction, resulting in a brown reaction product. Alternatively, in double labelling experiments binding sites of SMP were detected using fluorescein labelled antiserum to mouse immunoglobulin following treatment with neat SMP monoclonal antibody for 30 minutes and reaction with monoclonal antibody RT97 neurofilament antibody detected by layering on neat RT97 monoclonal antibody for 30 minutes followed by three washes with minimal essential medium and application of a peroxidase labelled antiserum to mouse immunoglobulin. This sequential treatment of the section with monoclonal antibodies SMP and RT97 did not result in non-specific binding, nor did it prevent binding of the second monoclonal antibody to the section. For silver staining sections were fixed in 10% neutral formalin for 30 minutes before carrying out the standard von Braunmuhl technique. Amyloid was detected with Congo red. The affinity of SMP monoclonal antibody for peripheral blood mononuclear cells was assessed using blood smears fixed in acetone and stained with SMP monoclonal antibody followed by fluorescein conjugated antimouse immunoglobulin. Binding of SMP to peripheral blood mononuclear cells was also studied using a fluorescence activated cell sorter (FACS). Samples of Macdonald, Esiri normal body tissues were screened for reactivity with SMP monoclonal antibody in frozen sections treated in the same way as the sections of cerebral cortex described above.
Results
Preliminary analysis of antibody containing supernatants showed that although no antibodies were produced which were specific for all aged peripheral blood mononuclear cells, a monoclonal antibody was produced (SMP) that reacted with about 2% of aged and young peripheral blood mononuclear cells ( .. I~~~~~~~~~~~~~~~~~~~~~~~~~~~F ig 2 Higher power view ofcryostat section ofAlzheimer cortex after reaction with SMP monoclonal antibody.
Example ofplaque indicated by arrow. x 500. Alzheimer brain sections with SMP were compared with the staining patterns obtained using silver staining (von Braunmiihl) and staining for amyloid (Congo red) and neurofilaments (monoclonal antibody RT973). The staining pattern of SMP reactivity was very similar at low and high power magnification to that obtained with silver staining of plaques (figs 1 and 2). The number of senile plaques identified with SMP and silver, counted at low power in 1-5 mm diameter circles, was very similar (35 with SMP, 37 with silver). SMP binding in plaques showed some overlap with amyloid as shown by Congo red staining but was more extensive. Leptomeningeal and cortical vessels in which amyloid was deposited in Alzheimer brain, however, showed coextensive binding of SMP (fig3). The neurofilament specific monoclonal antibody RT97 did not stain all plaques demonstrable with silver and SMP, but where plaques could be identified with RT97 there was also staining with SMP (fig 4) . SMP bound more extensively than RT97 to those plaques that were doubly reactive. Neurofibrillary tangles, which are strongly reactive with RT973, were also moderately reactive with SMP ( fig 5) . 
Discussion
These observations show that SMP binds to an epitope in Alzheimer brain, which has a distribution resembling that of the silver stained elements of argyrophilic plaques, congophilic elements in leptomeningeal and cortical blood vessels, and 1202 group.bmj.com on July 6, 2017 -Published by http://jcp.bmj.com/ Downloaded from neurofibrillary tangles. The SMP antigen, therefore, seems to be common to all these pathological features. The staining pattern obtained in Alzheimer brain differs from that obtained with the neurofilament antibody RT97 in that plaque staining was more extensive with SMP than with RT97 and the vascular amyloid was stained by SMP but not by RT97. By electron microscopy plaques seem to be composed of degenerate neuritic processes that contain mitochondria, dense bodies, and paired helical filaments resembling those of neurofibrillary tangles.' Astrocytic and microglial processes may also participate in plaque structure, and extracellular amyloid deposits can be identified in plaques. Astrocytes and microglial cells in and around resolving cerebral infarcts did not react with SMP. In normal brain SMP bound minimally and only to vascular elements. The observation of binding of SMP to a small proportion of peripheral blood mononuclear cells using the FACS could not be confirmed in blood smears. The SMP antigen, however, was clearly present in germinal centres of lymphoid follicles where it seemed to react with dendritic reticulum cells. Many antigenic determinants common to lymphoid and central nervous system tissues have been detected using other monoclonal antibodies,6 but to our knowledge none of these has been related to follicular dendritic cells, nor to Alzheimer brain. The biochemical nature of the SMP antigen has proved difficult to determine, and so far attempts to immunoprecipitate or immunoblot the antigen present in tonsil tissue and Alzheimer cerebral cortex have failed to establish the molecular weight of the antigen.
The findings presented here of an antigen common to cerebral amyloid, argyrophilic plaques, and neurofibrillary tangles in Alzheimer's disease support the suggestion by Kidd et al7 that these features share a common protein. Further investigations using this monoclonal antibody may prove of value in attempting to understand the nature of the neuronal degeneration that causes Alzheimer's disease.
